Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
The biotech's Rasonque is already available for prescription.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.